Contraline Appoints Medical Device Industry Leader Dr. Yelena Tropsha as Chief Technology Officer

  • Healthcare gadget product or service advancement and commercialization expert of 25 several years, Yelena Tropsha, PhD, joins Contraline as Chief Technologies Officer

  • Dr. Tropsha will spearhead endeavours to deliver Contraline’s male contraceptive device, ADAM, in the direction of Food and drug administration acceptance

CHARLOTTESVILLE, Va., March 30, 2022–(Company WIRE)–Contraline, Inc., a undertaking-backed health-related unit enterprise devoted to providing adult males with long-lasting, risk-free, and successful contraception has appointed professional medical gadget market leader Dr. Yelena Tropsha to the part of Main Technological innovation Officer.

This press launch attributes multimedia. See the full release in this article: https://www.businesswire.com/information/property/20220330005043/en/

Dr. Yelena Tropsha joins Contraline as Chief Engineering Officer (Picture: Company Wire)

Dr. Tropsha delivers to Contraline about 25 several years of health-related device working experience, from entrance-end innovation to commercialization. Dr. Tropsha served for 10 decades with Coloplast as Vice President of Implantable Devices, Urology the place she was liable for R&D, Scientific, Healthcare and Regulatory Affairs. Dr. Tropsha also held Vice Presidential positions with leading health care unit firms DYSIS Healthcare and Neuronetics and senior specialized positions at Medtronic and Becton Dickinson.

In excess of the course of her job, Dr. Tropsha has been involved in the progress, approvals, and launches of 19 Class II and Class III medical gadgets in urology and gynecology. In addition to healthcare gadget progress, her know-how is in materials science with emphasis on polymers and biomaterials. She is detailed as an inventor on above 25 patents and 20 publications.

“Yelena joins our crew at an remarkable time in advance of our initial-in-human clinical trial of ADAM™, the world’s initial injectable hydrogel built to offer prolonged-long lasting, non-long term vas-occlusion for adult males,” reported Kevin Eisenfrats, Co-Founder and Main Govt Officer of Contraline.

“We are charting the route to bring a innovative reproductive health-related system like ADAM™ to market. We are also starting to extend the probable takes advantage of for our hydrogel platform. We will considerably reward from Yelena’s practical experience foremost numerous organizations with revolutionary professional medical gadgets in urology and gynecology to effective regulatory and professional outcomes.”

At Contraline, Dr. Tropsha will spearhead R&D, regulatory affairs, and industry access. She will also lead endeavours to develop use of Contraline’s proprietary hydrogel system for new indications in reproductive health further than vas-occlusion.

“I am energized and honored to be section of Contraline’s group, symbolizing a new era in contraceptive technologies. Contraline’s work to establish a hydrogel for vas-occlusion draws from my parts of interest and experience: health care device development, urology, and polymer science. The possibility to travel the ADAM™ product from preclinical experiments through commercialization will be a job spotlight for me,” reported Yelena Tropsha.

Dr. Tropsha holds a master’s degree in Chemistry and a PhD in Polymer Science from Moscow State College in Russia.

About Contraline

Contraline, Inc. is a enterprise-backed professional medical product enterprise devoted to providing adult men and partners with extensive-long lasting, safe, and successful contraception. The corporation is building ADAM™, the world’s first injectable hydrogel built to supply prolonged-long lasting barrier contraception for guys. The organization was founded in 2015 by Kevin Eisenfrats and Dr. John Herr, and is headquartered in Charlottesville, Virginia. To discover more, stop by http://www.contraline.com

Watch resource variation on businesswire.com: https://www.businesswire.com/news/household/20220330005043/en/

Contacts

Kevin Eisenfrats
[email protected]